DIY Lab Testing for
Self-Sourced HRT & Peptides

The user came in with five concrete questions. Lead-with-answer format, then the supporting work in subsequent plates.

Side-by-side: who tests what, how they're funded, and whether they accept your form factor. Hover/tap a row for a contrasted background. The "endotoxin / oils?" column is the most operationally important.

The user's anchor question. Yes, with caveats. Specific kit, specific failure modes, specific arithmetic. The relevant pharmacopoeial chapters are USP <85> / EP 2.6.14 (LAL) and USP <86> / EP 2.6.32 (recombinant Factor C, rFC) — the latter became official in EP Suppl. 10.3 (effective 2021-01-01) and USP <86> in May 2025.

Hard requirements — the gotchas that will cost you the run

1. Depyrogenation, not sterilization. Autoclaving kills bacteria but does not destroy endotoxin (LPS is ~10× more heat-stable than spores). Glass that touches LAL or sample must bake at 250°C / ≥30 min (alt: 200°C / ≥60 min per Ph. Eur. 5.1.1) — or buy pyrogen-free disposables.
2. Positive Product Control every run. Spike your diluted sample with CSE at 2λ. If it doesn't clot, your matrix is inhibiting the assay and your "negative" is meaningless.
3. Oil interferes with LAL. For oil-based HRT (T enanthate in MCT, EV in grapeseed) do liquid–liquid extraction (1:1 LRW vortex, centrifuge, test aqueous phase) or dilute beyond the interference threshold. The LLE protocol is validated for kinetic chromogenic; for gel-clot, revalidate each new oil matrix with spiked CSE.
4. Water quality is critical. LAL Reagent Water must be certified <0.005 EU/mL. Sterile WFI and Milli-Q are not substitutes unless explicitly LRW-grade.
5. pH window 6–8. Outside this, lysate misbehaves. Adjust dilutions with pyrogen-free buffer.
6. Re-qualify λ on every lysate lot. Vendor λ is the label claim; your method λ is the lowest concentration that clots in 4-of-4 replicates with your CSE and your hands.

All prices are real listings or vendor catalogue snapshots dated 2026-04-22. Used-market prices drift weekly; treat the bands as planning numbers, not quotes. Dealers worth watching: LabX, EquipNet, BioSurplus, Marshall Scientific, Conquer Scientific, New Life Scientific, Labrepco, GovDeals, university surplus auctions.

HPLC — the workhorse

LC-MS / orthogonal ID

FTIR / UV-Vis / supporting

Microbiology & pyrogen

Recurring per-test consumables

What each technique tells you, what it costs to acquire used, and where it fits in the harm-reduction stack. RP-HPLC with UV/DAD is the universal core; everything else is orthogonal confirmation or a Bronze substitute.

The community-lab HPLC method, distilled

Three realistic build-outs at three price points. Each tier lists what it actually buys you and what it doesn't. Sticker price is what you spend on instruments & consumables; year-1 all-in includes install, software, standards, mobile-phase water, and waste disposal.

Drag the slider. The recommendation updates with what makes economic sense at your annual test volume, assuming you're choosing between in-house and shipping to Janoshik (~$120/test for steroid oils).

Every concentration number a lab reports is a comparison to a reference, so the chain of trust runs Primary → Secondary → Working. The CoA is the contract. Without one, the material is bulk API, not a reference standard.

Four federal agencies people worry about. Three of them aren't the issue. The fourth (DEA) only becomes relevant if you handle scheduled substances directly — and there's a well-trodden DEA-exempt path that avoids registration entirely.

From the failure-mode docs. The competence floor below which you get answers worse than no answers is real, but the failure modes are concrete and learnable.

1. Chase the right ester. EV vs EC vs EEn have different RT and MW. Calibrating against EV when the vial is EC makes your "potency" number meaningless.
2. Reference standard quality is the floor. Verify your RS by DAD spectrum (and ideally LC-MS) before using it to calibrate.
3. System suitability before every run. 5+ replicate injections, RSD <2%, plates >2,000, tailing <2.0. Skip this and you have no way to know your method is in control.
4. Always run a method blank. Carrier oil + diluent through the full prep, no API. Confirms no false signal from matrix or contamination.
5. For LAL: positive product control every run. Spike sample with CSE at 2λ. If it doesn't clot, your matrix is inhibiting; "negative" is meaningless.
6. Depyrogenation ≠ sterilization. Autoclave kills bacteria but does not destroy endotoxin. 250°C / 30 min dry heat or buy depyrogenated disposables.
7. Oil interferes with LAL. Liquid-liquid extract or dilute beyond MVD threshold for any oil-based HRT before testing.

Round I shipped breadth — every topic touched. Round II is depth of execution: protocols a competent operator could actually run on a refurb Agilent 1100 or an ACC Pyrotell kit, profiles of the labs that do this work today, the kit-level shootout, and the aggregate statistics that describe the ecosystem.

Every outfit that publishes anything resembling a gray-market testing service, profiled on a common schema. The single operationally load-bearing row at the bottom: no commercial lab in this set offers mail-in endotoxin testing for oil-based HRT injectables.

Capability summary (which lab does what, for what form factor)

Two procedures rendered as step-by-step numbered lists. Recipes have a copy button so you can paste straight into a lab notebook. Both SOPs in Round II are the reduced-to-practice versions of Round I methods — enough detail to execute, not enough to replace the full documents.

Methanol/water 80:20 (v/v) isocratic mobile phase — 1 L
===============================================================
 1. Measure 800 mL HPLC-grade methanol into a 1 L graduated
    cylinder.
 2. Add 200 mL HPLC-grade water (18.2 MΩ Milli-Q, fresh).
 3. Transfer to a 1 L amber solvent bottle. Cap with PTFE-lined
    closure.
 4. Degas: sonicate 10 min (bench sonicator), OR rely on the
    in-line G1322A vacuum degasser.
 5. Label with date, operator, lot. Shelf life: 2 weeks at RT
    in amber bottle.

Acetonitrile / 10 mM KH₂PO₄ pH 3 — 1 L (~80:20 ACN:buffer)
===============================================================
 1. Weigh 1.36 g KH₂PO₄ (ACS reagent grade) into a 200 mL
    beaker.
 2. Dissolve in ~150 mL Milli-Q water. Adjust to pH 3.0 with
    dilute orthophosphoric acid, pH meter calibrated that day.
 3. Transfer to 1 L volumetric; add 150 mL more Milli-Q.
 4. Add 800 mL HPLC-grade acetonitrile. Mix.
 5. Filter through 0.45 µm nylon into amber solvent bottle.
 6. Sonicate 10 min. Label with date / operator / lot.

Acetonitrile / water 85:15 (v/v) + 0.1% TFA or formic acid — 1 L
===============================================================
 1. Measure 850 mL HPLC-grade acetonitrile into a 1 L
    graduated cylinder.
 2. Add 150 mL HPLC-grade water (18.2 MΩ Milli-Q, fresh).
 3. Add 1.0 mL trifluoroacetic acid (TFA) for UV-only work
    OR 1.0 mL formic acid (FA) if the same mobile phase
    will see LC-MS later. Both give 0.1% (v/v).
       — TFA → sharper peak shape, ion-suppresses ESI
       — FA  → MS-compatible, slightly broader peaks
 4. Transfer to a 1 L amber solvent bottle. Cap with PTFE-
    lined closure. Mix by inversion 10×.
 5. Degas: sonicate 10 min, OR rely on the in-line G1322A
    vacuum degasser.
 6. Label with date, operator, lot, and additive (TFA vs FA).
    Shelf life: 1 week at RT in amber bottle (TFA degrades
    column bonded phase faster than phosphate; rinse the
    column with neat ACN/water 50:50 at end of day).

Use with: 4.6 × 50 mm C18 (Kinetex 2.6 µm, Poroshell 2.7 µm,
or ZORBAX Eclipse Plus 5 µm). Flow 1.0–1.5 mL/min, 30 °C.
Total run ~5 min. Single-ester potency only — sibling
ester resolution (EV/EEn/EC) drops; use Option A or B
on the 150 mm column for wrong-ester ID.

Endotoxin Limit (EU/mg) = K / M
Endotoxin Limit (EU/mL) = EL(EU/mg) × product concentration (mg/mL)
MVD                     = Endotoxin Limit (EU/mL) / λ

K = 5 EU/kg        (parenteral, non-intrathecal)
M = max dose/kg/hr (70 kg basis ⇒ allowable load 350 EU / dose)
λ = 0.25 EU/mL     (ACC Pyrotell G5250)

Testosterone cypionate 200 mg/mL:
  EL  = 350 / 200        = 1.75 EU/mg
  EL  = 1.75 × 200       = 350 EU/mL neat
  MVD = 350 / 0.25       = 1,400×

Estradiol valerate 40 mg/mL (monthly dose basis):
  EL  = 350 / 40         = 8.75 EU/mg
  MVD (at neat 350 EU/mL) = 1,400×

Every kit family a home or small-lab operator would realistically consider. Click a column header to sort. The cost-per-test rows below the main table show how the economics flip between volume tiers — a cartridge reader that looks expensive at 1 test/year becomes competitive at 50; PyroGene rFC becomes cheapest at 500.

Cost-per-test at three volume tiers (amortises reader + kit)

The checklist below persists to localStorage — tick items off during a physical inspection or video walkthrough; close the tab and come back. Below the checklist: the Agilent generation map, module-level failures with Agilent part numbers, the April 2026 price table (with the DIS-49376 $10,500 → $24,500 drift called out), and the four-tier decision framework.

Pre-purchase inspection checklist

Agilent generation map — what runs what software

Module-level failures — keep these Agilent part numbers bookmarked

April 2026 price table (verified listings & certified refurb)

Four-tier decision framework

Beyond-sticker first-year overhead

Peptides aren't HRT esters. UV-absorbing aromatic residues are the variable that decides whether 280 nm detection will work at all. Finnrick has published test counts per peptide across 204 vendors — that's the rightmost column. The zero-aromatic rows (BPC-157, TB-500 short) are the ones that kill labs relying on 280 nm detection without knowing.

Method baseline for all 8: C18 150×4.6×5 µm, MeOH/H₂O 80:20 isocratic, 1.0 mL/min, 30 °C, 10 µL, UV 280 nm + DAD. Each scenario describes what you'd see, what it means, and what you'd do next.

1. Passing EV (textbook, verified vendor)

   PASS 40 mg/mL EV in grapeseed, VERIFIED vendor.

   Main peak RT 8.20 min (RSD 0.1% across n=5). Tailing T=1.10, plates N=8,400, DAD spectral match vs USP RS 0.9995. Assay 99.2 ± 1.2% of label claim. File the COA. This is what a real pass looks like.

   Action: report + archive • Source: DD5 Scenario 1

2. Under-dosed vial — identity PASS, potency FAIL

   POTENCY FAIL Same vial visually as scenario 1.

   RT and DAD spectral match are indistinguishable from a clean pass. But peak area ~850,000 vs expected ~1,250,000 — back-calculates to 68.0% of label. Rule out precipitation, prep error, and calibration drift before flagging fraud. This is the most common community-lab finding by count.

   Action: re-run, re-prep, then flag • Source: DD5 Scenario 2

3. Wrong-ester substitution — EEn sold as EV

   IDENTITY FAIL Main peak at RT 9.6 min (RRT 1.17), not 8.20.

   DAD spectral match 0.996 — still passes a naive threshold check because all estradiol esters share the A-ring chromophore. Caught on RT, not on spectrum. LC-MS nails it: [M+H]⁺ for EV is 357.2, EEn 385.3, EC 397.3, EB 377.2. Always ID by RT + mass when the spectrum class matches.

   Action: reject batch; LC-MS confirm • Source: DD5 Scenario 3

4. Oxidation + plasticizer contamination

   CONTAMINATION 18-month-old vendor product.

   Main EV 94% area; free E2 2.0%; estrone 1.0% (C17 oxidation); late phthalate peak 3.0% at RT 15.2 min (stopper/closure leach). Do not inject. Rejection even though the main-peak assay would pass a ±10% check on its own.

   Action: reject; investigate closure • Source: DD5 Scenario 4

5. Process-impurity profile — good homebrew

   PASS (with notes) 99.3% area purity; six trace impurities 0.08–0.30%.

   Signature finding: 0.30% estradiol 3-valerate regioisomer (Rs 1.6 vs main peak). Valeric acid, free E2, estrone all sub-0.25%. Normal process profile — not a reason to reject.

   Action: report with impurity table • Source: DD5 Scenario 5

6. Semaglutide +16 Da oxidation (LC-MS, not UV)

   WARN 14-day-post-reconstitution vial.

   Main peak deconvolutes to 4113.6 Da (PASS). Minor peak at +16.0 Da = 4129.6 Da at 6% area — Trp³¹ oxidation (semaglutide has no Met). Exceeds the 2% biologics limit. The +16 impurity is invisible on UV 280 nm at this level; needs MS to catch.

   Action: reject batch; shorten use-after-reconstitution • Source: DD5 Scenario 6

7. Ghost peaks in blank injections

   SYSTEM ISSUE Two reproducible ghosts at RT 6.5 and 11.3 min in blanks.

   ~0.4% and 0.2% of typical main peak. Traced to aged methanol (opened >10 weeks). Aldehyde / non-volatile accumulation is the real mechanism — not peroxide (that's an ether problem). Replace the bottle, flush the system, re-run blanks to confirm.

   Action: replace solvents; re-run blanks • Source: DD5 Scenario 7

8. Column aging across 250 injections

   MAINTENANCE Tracked trend over 250 oil-matrix injections.

   RT 8.20 → 7.80 min; T 1.08 → 2.30; N 8,400 → 3,500; pressure +30%. Signature points to bed-void formation + head-frit fouling from oil-matrix particulates — not silanol aging. Oil-matrix dilute-and-shoot lifetimes ~200–300 injections; with guard + LLE ~600–1,000.

   Action: replace head frit or column; switch to LLE prep • Source: DD5 Scenario 8

Pooled community testing data across the three published sources. The "lower bound of problems / upper bound of quality" framing applies throughout: self-selection (people test vials they already suspect) inflates fail rates; sampling bias against HRT (Finnrick is peptide-only, testing.trans.diy n=4) makes the HRT picture artificially clean.

HRT picture — what little data exists

Per-compound-class breakdown

Terms used throughout the manual.

Two services worldwide accept anabolic-androgenic steroids as a formal intake class on state or insurance money. Neither accepts HRT for gender-affirming care today — but both run instruments that already analyse oil-based hormone injectables. The bottleneck is scope-of-acceptance policy, not technical capability.

There is no peer-reviewed evidence base for community testing of DIY HRT. The closest analogs are the AAS literature, the recreational-drug-checking literature, and the WHO-commissioned systematic review that confirms the gap. These are the bounding priors that recalibrate user expectations.

The honest list. C5 = "we looked, we didn't find, here's why." Round III closed ten previously-listed gaps; the remaining residual is below.

• Krause Analytical methodology PDF content. Finnrick's biggest partner (3,836 / 6,813 tests = 56.3%). Their methodology questionnaire is an image-only scanned PDF — neither pymupdf nor pymupdf4llm extracted any text. Still the biggest known-unknown in the entire Finnrick partner corpus.Closing this: OCR with tesseract or marker-pdf; confirm instrument claims.
• TrustPointe endotoxin acceptance for oil-based HRT. Landing page lists endotoxin testing but does not say whether they accept oil-based HRT injectables. The single decision-relevant unknown that would change whether an oil-HRT user can outsource endotoxin at all.Closing this: direct email to TrustPointe with a stated oil matrix.
• Janoshik "Peter Magic" legal identity. Round III searched specifically; the community-rumored "Jan Orčík" name did not corroborate against janoshik.com/about-us/, the Northdata Czech business-registry aggregator entry for IČO 17668727, or the Peptide Protocol Wiki review. Treat as unverified rumour. The pseudonymous "Peter Magic" identity is the public-source ground truth.Closing this would require Czech corporate-registry officer-detail behind subscriber wall.
• Artemis Analytical principals + state + accreditation. Round III closed methodology, cost, scale (HPLC-UV + GC-MS, $0/submitter, $60 materials, 1-week TAT, two-volunteer admin); principals, state, and accreditation status remain unknown.Closing this: direct contact via testing@artemisanalytical.cc.
• Trans Harm Reduction's commercial GC-MS partner. THR publishes that they outsource to a commercial EU lab but does not name which one. Likely opsec for a partner that prefers not to be associated with mutual-aid trans work.Closing this: outreach to Mouse El Baba.
• Trans Harm Reduction's in-house instrument status. €6,750 / €6,800 (99%) raised; status now "Donations paused"; 20-month silence since the most recent THR-published test (2023-08-31). No public announcement of instrument purchase or operational status.Closing this: outreach via the THR Mastodon / Instagram channels.
• Specific HPLC method conditions used by community HRT labs. Artemis discloses HPLC-UV + GC-MS technique class only; Krause discloses instrument families only. No column part number, mobile phase, flow, wavelength, or system-suitability data is published anywhere.Reconstruction is C2–C3, not direct disclosure.
• Finnrick endotoxin price. $110 reported by peppal.app; not visible on finnrick.com directly. Login-gated paid tier.C3 for $110; C5 for an authoritative Finnrick number.
• Janoshik live pricing for SARMs ($170), HGH ($420), Package A ($828). /pricelist navigation restructured; some category prices visible only through the "Select a Test" submission flow. Sourced from PPW review and graymarket substack.
• USP estradiol valerate monograph specific text. Paywalled to USP subscribers; FTP mirrors returned socket errors. Method conditions reconstructed from peer-reviewed literature.C2–C3 reconstruction; C5 for verbatim USP text.
• Wako PYROSTAR ES-F live pricing. Fisher catalog behind sign-in wall; some secondary snippets suggest ~$454 for 200T — flag for re-verification before ordering.
• HRT endotoxin & sterility test volume — zero public data. No community lab publishes endotoxin results on oil-based HRT; no commercial mail-in option accepts oil-based HRT. Everything about real-world contamination rates in this form-factor is inference.
• Aggregated HRT vendor failure rates. testing.trans.diy has 4 tests (all PASS, n too small). THR has ~16 narrative results. No aggregated batch-failure statistics for HRT comparable to Finnrick's peptide A–F scoring. Round III note: the closest external prior is Piatkowski 2025a (13% wrong-substance in n=23 AAS pilot) — see Plate XX.
• Per-matrix gel-clot LAL spike recovery for non-MCT oils. DD2 is explicit that only fractionated coconut oil has published PPD Labs validation, and only for kinetic turbidimetric. Per-matrix gel-clot is an extrapolation each lab must validate.
• JP rFC standalone chapter status (Japanese Pharmacopoeia). Draft chapter on alternative endotoxin testing existed in 2020; no formal promulgation surfaced in English-language sources.
• DEA Form 225 fee 2026 current. $244/yr last seen on cached DEA pages; not date-stamped this pass.
• Community-lab aseptic-technique noise floor. What's the typical false-positive rate for a home USP <71>-style screen with a tabletop LAF in a normal room? Numbers exist in pharma QA records, not in public literature.
• Fake-COA prevalence on Janoshik. Documented individual cases (Modern Peptides etc.) but no systematic study. Janoshik's "verify COA" feature lets buyers check against the database — but no aggregate forgery rate is published.

Live URLs the corpus draws from. Verify-then-trust — especially the price bands, which drift weekly.